.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Orexin-A quantification in CSF is the clinical gold standard for diagnosing narcolepsy type 1 (NT1). However, traditional radioimmunoassays (RIA) often produce inaccurate results due to cross-reactivity and overestimation. Furthermore, this discrepancy has led to a long-standing conundrum regarding the presence of orexin in peripheral blood. Consequently, researchers have developed an optimized LC-MS/MS method that provides significantly higher sensitivity. Therefore, this method ensures superior diagnostic reliability for neurologists and sleep specialists.
Specifically, the new ultrasensitive method incorporates a streamlined one-step protein precipitation protocol. In addition, it utilizes acid-shielding and cocktail-protection strategies to mitigate enzymatic degradation. Moreover, the lower limit of quantification (LLOQ) reached an impressive 0.1 pg/mL. As a result, verification in paired CSF and blood samples revealed that orexin-B and peripheral orexins remain consistently below detection limits. Thus, this finding confirms that orexin is effectively absent from the peripheral blood of narcolepsy patients. Consequently, clinicians should continue to rely exclusively on CSF analysis for definitive biochemical diagnosis.
Moreover, the study demonstrates that the streamlined protocol reduces nonspecific adsorption. Therefore, this optimization makes the LC-MS/MS approach more practical for high-throughput clinical laboratories. Furthermore, identifying the absence of peripheral orexin simplifies the diagnostic algorithm. In contrast to older RIA techniques, this refined method eliminates the risk of false positives caused by peptide fragments. Finally, these advancements represent a significant step toward standardizing narcolepsy biomarkers globally.
LC-MS/MS offers much higher specificity and sensitivity. Unlike RIA, it avoids cross-reactivity with other proteins, ensuring more accurate Orexin-A quantification in CSF.
No, this optimized study confirms that orexin levels in peripheral blood remain below detection limits. Therefore, blood tests are currently not viable for narcolepsy diagnosis.
The method uses acid-shielding and a cocktail-protection strategy. These steps protect the peptide from enzymatic degradation and nonspecific adsorption, ensuring sample stability.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Cao Y et al. Tackling the Orexin Conundrum: An Optimized LC-MS/MS Method Demonstrates Accurate CSF Quantification and Absence in Peripheral Blood. Anal Chem. 2026 May 12. doi: 10.1021/acs.analchem.6c00454. PMID: 42118575.
Lindström M, et al. Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays. Clin Biochem. 2021 Apr;90:34-39. doi: 10.1016/j.clinbiochem.2021.01.009. PMID: 33539807.
Vialaret J, et al. 16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy. Sleep. 2025. doi: 10.1093/sleep/zsaf237. PMID: 40801283.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study introduces an optimized LC-MS/MS method for accurate CSF Orexin-A quantification, resolving the conundrum of its presence in peripheral blood....
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
